Unknown

Dataset Information

0

Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.


ABSTRACT: The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that amantadine and hexamethylene-amiloride (HMA), but not rimantadine, block the ion channel activity of Protein E from SARS-CoV-2, a conserved viroporin among coronaviruses. These findings agree with their binding to Protein E as evaluated by solution NMR and molecular dynamics simulations. Moreover, we identify two novel viroporins of SARS-CoV-2; ORF7b and ORF10, by showing ion channel activity in a X. laevis oocyte expression system. Notably, amantadine also blocks the ion channel activity of ORF10, thereby providing two ion channel targets in SARS-CoV-2 for amantadine treatment in COVID-19 patients. A screen of known viroporin inhibitors on Protein E, ORF7b, ORF10 and Protein 3a from SARS-CoV-2 revealed inhibition of Protein E and ORF7b by emodin and xanthene, the latter also blocking Protein 3a. This illustrates a general potential of well-known ion channel blockers against SARS-CoV-2 and specifically a dual molecular basis for the promising effects of amantadine in COVID-19 treatment. We therefore propose amantadine as a novel, cheap, readily available and effective way to treat COVID-19.

SUBMITTER: Toft-Bertelsen TL 

PROVIDER: S-EPMC8636635 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.

Toft-Bertelsen Trine Lisberg TL   Jeppesen Mads Gravers MG   Tzortzini Eva E   Xue Kai K   Giller Karin K   Becker Stefan S   Mujezinovic Amer A   Bentzen Bo Hjorth BH   B Andreas Loren L   Kolocouris Antonios A   Kledal Thomas Nitschke TN   Rosenkilde Mette Marie MM  

Communications biology 20211201 1


The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that amantadine and hexamethylene-amiloride (HMA), but not rimantadine, block the ion channel activity of Protein E from SARS-CoV-2, a conserved viroporin among coronaviruses. These findings agree with their binding to Protein E as evaluated by solution NMR  ...[more]

Similar Datasets

| S-EPMC8063946 | biostudies-literature
| S-EPMC8537953 | biostudies-literature
| S-EPMC9411598 | biostudies-literature
| S-SCDT-EMM-2022-15904 | biostudies-other
2025-02-24 | E-MTAB-14669 | biostudies-arrayexpress
| S-EPMC8850628 | biostudies-literature
| S-EPMC7546787 | biostudies-literature
| S-EPMC9055522 | biostudies-literature
| S-EPMC9032918 | biostudies-literature